Drug Profile
Research programme: human embryonic stem cell based therapeutics - ImStem Biotechnology
Alternative Names: IMS 002; IMSB 001; IMSO 001; IMSP 001Latest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator ImStem Biotechnology
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Graft-versus-host disease
- No development reported Arthritis; Bone disorders; Burns; Corneal disorders; Diabetic foot ulcer; Inflammatory bowel diseases; Sjogren's syndrome; Spinal cord injuries
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for preclinical development in Bone-disorders in USA
- 28 Aug 2022 No recent reports of development identified for preclinical development in Diabetic-foot-ulcer in USA (Topical)
- 28 Aug 2022 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA (Parenteral)